TY - JOUR
T1 - Sex differences in clinical characteristics and prognosis of patients with cardiac sarcoidosis
AU - Iso, Takashi
AU - Maeda, Daichi
AU - Matsue, Yuya
AU - Dotare, Taishi
AU - Sunayama, Tsutomu
AU - Yoshioka, Kenji
AU - Nabeta, Takeru
AU - Naruse, Yoshihisa
AU - Kitai, Takeshi
AU - Taniguchi, Tatsunori
AU - Tanaka, Hidekazu
AU - Okumura, Takahiro
AU - Baba, Yuichi
AU - Minamino, Tohru
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/4/25
Y1 - 2023/4/25
N2 - Objective Owing to the paucity of data, this study aimed to investigate sex differences in clinical features and prognosis of patients with cardiac sarcoidosis (CS). Methods This study was a secondary analysis of the ILLUstration of the Management and prognosIs of JapaNese PATiEnts with Cardiac Sarcoidosis registry - a retrospective multicentre registry that enrolled patients with CS between 2001 and 2017. The primary outcome was potentially fatal ventricular arrhythmia events (pFVAEs) - a composite of sudden cardiac death, sustained ventricular tachycardia lasting >30 s, ventricular fibrillation or the requirement for implantable cardioverter defibrillator therapy. Results Of the 512 participants (mean age±SD 61.6±11.4 years), 329 (64.2%) were females. Both sexes had peak ages of 60-64 years at diagnosis. Male patients were younger and had a higher prevalence of coronary artery disease and lower left ventricular ejection fraction than female patients. During a median follow-up of 3 years (IQR 1.6-5.6), pFVAEs were observed in 99 patients, with males having a significantly higher risk than females (p=0.002). This association was retained even after adjustment for other risk factors for pFVAEs, including left ventricular ejection fraction (adjusted HR 1.80; 95% CI 1.08 to 3.01, p=0.025). Conclusion Approximately two-thirds of patients with CS were females, with a peak age of approximately 60 years at clinical diagnosis in both sexes; male patients were younger than female patients. Male patients had a significantly higher risk of pFVAEs than female patients. Trial registration number UMIN000034974.
AB - Objective Owing to the paucity of data, this study aimed to investigate sex differences in clinical features and prognosis of patients with cardiac sarcoidosis (CS). Methods This study was a secondary analysis of the ILLUstration of the Management and prognosIs of JapaNese PATiEnts with Cardiac Sarcoidosis registry - a retrospective multicentre registry that enrolled patients with CS between 2001 and 2017. The primary outcome was potentially fatal ventricular arrhythmia events (pFVAEs) - a composite of sudden cardiac death, sustained ventricular tachycardia lasting >30 s, ventricular fibrillation or the requirement for implantable cardioverter defibrillator therapy. Results Of the 512 participants (mean age±SD 61.6±11.4 years), 329 (64.2%) were females. Both sexes had peak ages of 60-64 years at diagnosis. Male patients were younger and had a higher prevalence of coronary artery disease and lower left ventricular ejection fraction than female patients. During a median follow-up of 3 years (IQR 1.6-5.6), pFVAEs were observed in 99 patients, with males having a significantly higher risk than females (p=0.002). This association was retained even after adjustment for other risk factors for pFVAEs, including left ventricular ejection fraction (adjusted HR 1.80; 95% CI 1.08 to 3.01, p=0.025). Conclusion Approximately two-thirds of patients with CS were females, with a peak age of approximately 60 years at clinical diagnosis in both sexes; male patients were younger than female patients. Male patients had a significantly higher risk of pFVAEs than female patients. Trial registration number UMIN000034974.
KW - cardiomyopathies
KW - epidemiology
KW - tachycardia, ventricular
KW - ventricular fibrillation
UR - https://www.scopus.com/pages/publications/85159417108
UR - https://www.scopus.com/pages/publications/85159417108#tab=citedBy
U2 - 10.1136/heartjnl-2022-322243
DO - 10.1136/heartjnl-2022-322243
M3 - Article
C2 - 37185298
AN - SCOPUS:85159417108
SN - 1355-6037
VL - 109
SP - 1387
EP - 1393
JO - Heart
JF - Heart
IS - 18
ER -